Abstract
Understanding early innate immune responses to coronavirus disease 2019 (COVID–19) is crucial to developing targeted therapies to mitigate disease severity. Severe acute respiratory syndrome coronavirus (SARS-CoV)-2 infection elicits interferon expression leading to transcription of IFN-stimulated genes (ISGs) to control viral replication and spread. SARS-CoV-2 infection also elicits NF-κB signaling which regulates inflammatory cytokine expression contributing to viral control and likely disease severity. Few studies have simultaneously characterized these two components of innate immunity to COVID-19. We designed a study to characterize the expression of interferon alpha-2 (IFNA2) and interferon beta-1 (IFNB1), both type-1 interferons (IFN-1), interferongamma (IFNG), a type-2 interferon (IFN-2), ISGs, and NF-κB response genes in the upper respiratory tract (URT) of patients with mild (outpatient) versus severe (hospitalized) COVID-19. Further, we characterized the weekly dynamics of these responses in the upper and lower respiratory tracts (LRTs) and blood of severe patients to evaluate for compartmental differences. We observed significantly increased ISG and NF-κB responses in the URT of mild compared with severe patients early during illness. This pattern was associated with increased IFNA2 and IFNG expression in the URT of mild patients, a trend toward increased IFNB1-expression and significantly increased STING/IRF3/cGAS expression in the URT of severe patients. Our by-week across-compartment analysis in severe patients revealed significantly higher ISG responses in the blood compared with the URT and LRT of these patients during the first week of illness, despite significantly lower expression of IFNA2, IFNB1, and IFNG in blood. NF-κB responses, however, were significantly elevated in the LRT compared with the URT and blood of severe patients during peak illness (week 2). Our data support that severe COVID-19 is associated with impaired interferon signaling in the URT during early illness and robust pro-inflammatory responses in the LRT during peak illness.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported by the intramural research programs of the National Institutes of Health Clinical Center and the National Institute of Allergy and Infectious Diseases and under Contract No. HHSN272201800013C through Laulima Government Solutions, LLC or Tunnell Government Services, Inc.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Patients with severe COVID-19 were admitted to the National Institutes of Health Clinical Center (NIHCC) and enrolled in the Adaptive COVID-19 Treatment Trial (ACTT-1) (#20-0006). These patients were co-enrolled in the Admission and Management of Occupational or Other Exposures to Biodefense/Bioterrorism Agents or to Epidemic/Emerging Infectious Diseases (AMOEBAE) protocol (#10-I-0197) for serial collection of blood and respiratory specimens. Outpatients with mild COVID-19 were enrolled in the National Institute of Health Transmissibility and Viral Load of SARS-CoV-2 Through Oral Secretions Study (Study Number, NCT04348240, National Institutes of Health IRB 20-D-0094). Healthy control blood samples were collected under the National Institutes of Health approved protocol Number: 17-I-0016 (NCT02974595): Studies of the Natural History, Pathogenesis, and Outcome of Autoinflammatory Diseases (NOMID/CAPS DIRA CANDLE SAVI NLRC4-MAS Still-like Diseases and other Undifferentiated Autoinflammatory Diseases). Deidentified healthy control respiratory samples were provided by the Department of Laboratory Medicine at the NIHCC. These samples that were fully deidentified to all study team members were deemed non-human subject research by the NIH Office of Human Subject Research Protection (OHSRP) in accordance with Federal Policy for the Protection of Human Subjects at 45 CFR 46.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Data produced in the present work are contained in the manuscript and supplementary figures.
